The final results of the pivotal PRISMA-3 study show the efficacy of both dosage strengths of the monthly injectable antipsychotic for the treatment of patients with acute exacerbation of schizophrenia.
Fri, 05/07/2019 - 12:15 The final results of the pivotal PRISMA-3 study show the efficacy of both dosage strengths of the monthly injectable antipsychotic for the treatment of patients with acute exacerbation of schizophrenia.
Comments
Add new comment